A Phase 2 Study of Pembrolizumab in Combination With Pelareorep in Patients With Advanced Pancreatic Adenocarcinoma
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2018
At a glance
- Drugs Pelareorep (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 26 Nov 2018 According to an Oncolytics Biotech media release, the company today announced that the first patient has been treated in this study.
- 26 Nov 2018 Status changed from not yet recruiting to recruiting, according to an Oncolytics Biotech media release.
- 02 Nov 2018 New source identified and integrated (ClinicalTrials.gov; NCT03723915).